FIGURE 1.
Ascertainment of first moderate and severe anaphylactic reactions following intravenous immunoglobulin (IvIg) administrations between 1 January 2009 and 31 December 2018. 1 Same epinephrine product and dose administered during the hospitalization on a different day without IvIg use (one epinephrine administration before IvIg or ≥ two epinephrine administrations after IvIg); 2 e.g. during bronchoscopy, endoscopy or epistaxis; 3e.g. for control of exacerbation of chronic spontaneous urticaria. 4Other reasons observed were: surgical procedures, Kawasaki disease and cerebral‐induced hypotension